TrinityPoint Wealth LLC Takes $234,000 Position in Insulet Co. (NASDAQ:PODD)

TrinityPoint Wealth LLC acquired a new position in Insulet Co. (NASDAQ:PODD - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 897 shares of the medical instruments supplier's stock, valued at approximately $234,000.

Several other large investors have also recently added to or reduced their stakes in the business. SBI Securities Co. Ltd. bought a new stake in shares of Insulet during the 4th quarter worth $36,000. Itau Unibanco Holding S.A. acquired a new position in Insulet during the fourth quarter valued at $42,000. SRS Capital Advisors Inc. lifted its position in shares of Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock worth $49,000 after purchasing an additional 56 shares in the last quarter. Assetmark Inc. boosted its holdings in shares of Insulet by 1,447.1% during the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock worth $69,000 after purchasing an additional 246 shares during the period. Finally, Blue Trust Inc. lifted its position in Insulet by 117.3% in the 4th quarter. Blue Trust Inc. now owns 276 shares of the medical instruments supplier's stock worth $72,000 after buying an additional 149 shares in the last quarter.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Raymond James reiterated an "outperform" rating and set a $328.00 price objective (up from $294.00) on shares of Insulet in a report on Friday, February 21st. Barclays upped their target price on Insulet from $234.00 to $266.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 30th. Sanford C. Bernstein reaffirmed an "outperform" rating on shares of Insulet in a research report on Friday, May 16th. Oppenheimer lifted their target price on Insulet from $312.00 to $324.00 and gave the stock an "outperform" rating in a research report on Friday, May 9th. Finally, Royal Bank of Canada assumed coverage on shares of Insulet in a research note on Thursday, March 6th. They issued an "outperform" rating and a $340.00 price objective for the company. Four analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $308.00.

Insulet Stock Performance

PODD traded down $3.50 on Thursday, reaching $321.00. The company had a trading volume of 991,446 shares, compared to its average volume of 708,855. The stock has a market cap of $22.59 billion, a P/E ratio of 55.44, a P/E/G ratio of 3.62 and a beta of 1.26. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. Insulet Co. has a fifty-two week low of $170.67 and a fifty-two week high of $329.33. The company's fifty day moving average is $268.73 and its 200 day moving average is $268.38.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.81 by $0.21. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The company had revenue of $569.00 million during the quarter, compared to analysts' expectations of $543.20 million. During the same quarter in the previous year, the business posted $0.73 earnings per share. Insulet's quarterly revenue was up 28.8% on a year-over-year basis. As a group, analysts predict that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Insider Buying and Selling at Insulet

In other news, SVP John W. Kapples sold 5,278 shares of the stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total value of $1,680,884.66. Following the completion of the sale, the senior vice president now owns 23,180 shares of the company's stock, valued at approximately $7,382,134.60. This represents a 18.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Wayne A.I. Frederick sold 1,825 shares of the firm's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the transaction, the director now owns 3,231 shares of the company's stock, valued at approximately $888,525. The trade was a 36.10% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.39% of the company's stock.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.